Which Coronavirus Stock Could Fetch Higher Returns? Following the rapid vaccination drives across the world last year, the demand for Covid-19 vaccines is declining. However, booster doses targeting new subvariants are expected to drive sales for coronavirus stocks in the days ahead. Recently, the U.S. Food and Drug Administration (FDA) advised Covid-19 vaccine makers to update their booster shots, scheduled for this fall, to include components that could combat the currently dominant Omicron BA.4 and BA.5 subvariants. Given the uncertainty associated with Covid-19, it is difficult to determine the demand for vaccines in 2023 and the year ahead. 7 Best Biotech Stocks to Buy in July 2022 Amid this backdrop, I used the TipRanks Stock Comparison Tool to compare the following coronavirus vaccine makers to pick the stock that could offer a higher upside from current levels. Ticker Company Price PFE Pfizer Inc. $53.44 MRNA Moderna, Inc. $176.18 NVAX Novavax, Inc. $71.06 Coronavirus Stocks: Pfizer (PFE) Source: Manuel Esteban | Shutterstock.com Pfizer’s (NYSE: PFE ) Fiscal 2022 guidance indicates that the biopharmaceutical giant’s revenue could cross the $100 billion mark, thanks to the Pfizer-BioNTech Covid-19 vaccine, Comirnaty , and oral antiviral pill, Paxlovid .